Andrew Scott Paulson - Researcher Profile

Publications

2 shown

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu , Richard S. Finn , Julien Edeline +56 more

2018 The Lancet Oncology 2448 citations

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

Ghassan K. Abou‐Alfa , Vaibhav Sahai , Antoine Hollebecque +16 more

Fibroblast growth factor receptor (FGFR) 2 gene alterations are involved in the pathogenesis of cholangiocarcinoma. Pemigatinib is a selective, potent, oral inhibitor of FGFR1, ...

2020 The Lancet Oncology 1455 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 3,903
Institution: Baylor University Medical Center

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0009-0000-6023-670X

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.